On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments f

The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paed

Topic Editor Johannes N. van den Anker is the Chief Medical Officer at Reveragen Biopharma, as well as holding his positions at academic institutions. The other

The GAP-f Phase 2 Progress Report highlights the network’s achievements and milestones from 2022 to 2024, providing a transparent overview of its impact. The